Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia | Zendy

Deepak L. Bhatt | Zendy; Philippe Gabríel Steg | Zendy; Michael Miller | Zendy; Eliot A. Brinton | Zendy; Terry A. Jacobson | Zendy; Steven Ketchum | Zendy; Ralph T. Doyle | Zendy; Rebecca A. Juliano | Zendy; Lixia Jiao | Zendy; Craig Granowitz | Zendy; JeanClaude Tardif | Zendy; Christie M. Ballantyne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Author(s) -

Deepak L. Bhatt,

Philippe Gabríel Steg,

Michael Miller,

Eliot A. Brinton,

Terry A. Jacobson,

Steven Ketchum,

Ralph T. Doyle,

Rebecca A. Juliano,

Lixia Jiao,

Craig Granowitz,

JeanClaude Tardif,

Christie M. Ballantyne

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1812792

Subject(s) - hypertriglyceridemia , reduction (mathematics) , medicine , cardiology , triglyceride , cholesterol , geometry , mathematics

Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore